Dr. Caughey studies various aspects of cancer treatment, especially how to prevent and manage complications like blood clots in patients with advanced cancer. He investigates the effectiveness of different treatments, including the blood thinner enoxaparin and the flavonoid isoquercetin, to reduce the risk of thromboembolic events, which are blood clots that can lead to serious health issues. His research also looks at how support from healthcare providers, like pharmacists and nurses, can impact patients' adherence to oral chemotherapy, helping to identify ways to improve treatment success.
Key findings
Isoquercetin reduced D-dimer levels by about 21.9%, indicating a decrease in blood clot risk for cancer patients after taking 1000 mg daily for 56 days.
Only 14% of patients using pharmacist support dropped out of their oral chemotherapy regimen compared to 7% for those receiving nurse support, highlighting differences in treatment adherence.
Patients taking enoxaparin had a 5.6% incidence of blood clots, while those not receiving preventive treatment experienced a 27.3% incidence, showing a significant reduction in risk.
Frequently asked questions
Does Dr. Caughey study blood clots in cancer patients?
Yes, Dr. Caughey focuses on preventing blood clots in cancer patients, particularly through treatments like enoxaparin and isoquercetin.
What treatments has Dr. Caughey researched?
He has researched blood thinners like enoxaparin and the flavonoid isoquercetin as potential treatments to reduce blood clot risks in cancer patients.
Is Dr. Caughey's work relevant to cancer patients?
Absolutely, his research provides valuable insights into managing common complications faced by cancer patients, such as blood clots, and improving their treatment adherence.
Publications in plain English
Adherence to oral chemotherapy: Challenges and opportunities.
2019
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
Krikorian S, Pories S, Tataronis G, Caughey T, Chervinsky K +3 more
Plain English This study looked at how well cancer patients stick to their oral chemotherapy by comparing the support they received from pharmacists versus nurses. Out of 200 patients, those in the pharmacist group had a dropout rate of 14%, while the nurse-led group had a 7% dropout rate. Most patients in both groups were compliant with their medication, but issues like forgetfulness and feelings of depression affected adherence, highlighting the need for better support strategies.
Who this helps: This research benefits cancer patients by identifying ways to improve their treatment adherence.
Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer.
2019
JCI insight
Zwicker JI, Schlechter BL, Stopa JD, Liebman HA, Aggarwal A +12 more
Plain English This study focused on a substance called isoquercetin, which was tested to see if it could help cancer patients who are at high risk of developing blood clots. Researchers found that taking 1000 mg of isoquercetin daily for 56 days reduced D-dimer levels (a marker of blood clot formation) by about 21.9% and significantly decreased other indicators of blood clot risk without causing serious side effects like blood clots or major bleeding. This matters because it shows that isoquercetin can potentially help manage blood clot risks in patients with advanced cancer.
Who this helps: Cancer patients at high risk for blood clots.
Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study).
2013
British journal of haematology
Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F +10 more
Plain English This study looked at how well a medication called enoxaparin can prevent blood clots in cancer patients who have high levels of certain tiny particles associated with clotting. It found that only 5.6% of patients on enoxaparin developed blood clots compared to 27.3% of those who did not receive the medication. This is important because it shows that enoxaparin can significantly lower the risk of blood clots, which can be a serious complication for cancer patients.
Who this helps: This helps cancer patients who are at risk of developing blood clots.
Jeffrey I Zwicker Howard A Liebman Kenneth A Bauer Donna Neuberg Bruce Furie Benjamin L Schlechter Jack D Stopa Anita Aggarwal Maneka Puligandla Nancy Kuemmerle
Physician data sourced from the
NPPES NPI Registry
.
Publication data from
PubMed
.
Plain-English summaries generated by AI.
Not medical advice.